In subset 1, patients with PRL-3-positive breast carcinomas showed a trend towards shorter DFS compared to patients with PRL-3-negative cancers (83±4 months (95% CI, 74–91) vs 89±8 months (95% CI, 74–105), respectively). The gene discussed is PTP4A3; the disease is breast carcinoma.